Promising Developments at Anixa Biosciences: Buy Rating Reiterated with $7 Price Target

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $7.00.

Yi Chen’s rating is based on several promising developments at Anixa Biosciences. The company has successfully completed enrollment for its Phase 1 trial of a breast cancer vaccine, which is being developed in collaboration with the Cleveland Clinic and funded by the U.S. Department of Defense. The trial involves diverse cohorts, including women at risk of recurrence and those with genetic predispositions, and has shown encouraging preliminary data with over 70% of participants exhibiting an immune response.
Additionally, Anixa Biosciences has made significant progress in its CAR-T therapy for ovarian cancer. An amendment to the trial protocol now allows for a second dose of the therapy and expands eligibility to include additional rare cancer types, potentially enhancing the treatment’s efficacy. Financially, the company reported a manageable net loss for fiscal 2Q25 and maintains a solid cash position, which is expected to support operations into 2027. These factors contribute to the reiterated Buy rating and a price target of $7.